Evaluating the combination and comparison of ablative fractional lasers (CO2, Erbium-YAG) with pulsed dye laser (PDL) for treating hypertrophic scars: a systematic review.

Journal: Lasers In Medical Science
Published:
Abstract

The aim of this study is to compare pulsed dye laser (PDL) and ablative fractional lasers (CO2, Erbium-YAG) in the treatment of hypertrophic scars in a systematic review. Databases including Web of Science, Science Direct, Google Scholar and PubMed were searched for clinical trials up to December 1, 2022; focusing on the role of ablative fractional lasers and pulsed dye lasers in treating hypertrophic scars, using comprehensive keywords and search syntaxes. Key data extracted included type of scars, the assessment indexes, treatment modalities, side effects and the final conclusion of each article. We found no significant difference between the PDL and the ablative fractional laser in the treatment of hypertrophic scars, and both showed significant improvement. The average number of treatment sessions in the group receiving ablative fractional laser was 3.43 sessions, in the group receiving PDL, 3.68 sessions, and in the group receiving the combination of the two lasers, 1.5 sessions. Ablative fractional laser was 57.5% effective in VSS scoring and 40.4% effective in POSAS scoring, while PDL laser was 49.4% effective in VSS scoring and 35.5% effective in POSAS scoring, also the combination of both methods may lead to better results and higher efficacy with no severe adverse reactions noted. More high-quality trials are needed to fully confirm the effectiveness of laser therapy. Ablative fractional laser and PDL are both effective in treating hypertrophic scars and there was no significant difference between them. However, studies investigating the combination of these two lasers have reported greater effectiveness than each method alone.

Authors
Mohammadreza Ghassemi, Pardissadat Mireshghollah, Alireza Jafarzadeh, Farnoosh Seirafianpour, Elham Behrangi, Sara Montazeri Namin, Mina Khosravi, Azadeh Goodarzi